New MS biosimilar aims to match leading Drug's effect
Disease control
Recruiting now
This study tests whether a new drug called CYB704 works as well as the approved drug Ocrevus for people with relapsing multiple sclerosis (MS). About 175 adults with active MS will receive either CYB704 or Ocrevus and be monitored with regular checkups and MRI scans. The goal is …
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC